Media Center Banner

NEWS RELEASE

Released: April 11, 2013

Department of Defense Amyotrophic Lateral Sclerosis Research Program
Anticipated Funding Opportunities for Fiscal Year 2013 (FY13)

The FY13 Defense Appropriations Act provides $7.5 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) to support innovative, high-impact research into Amyotrophic Lateral Sclerosis (ALS). The Department of Defense ALSRP is administered by the US Army Medical Research and Materiel Command (USAMRMC) through the Office of Congressionally Directed Medical Research Programs (CDMRP).

The ALSRP is providing this information to allow investigators time to plan and develop applications. FY13 ALSRP program announcements and general application instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May 2013. This pre-announcement should not be construed as an obligation by the government.

Mechanism Eligibility Key Mechanism Elements Funding
Therapeutic Development Award Independent investigators at all academic levels
  • Supports preclinical development of therapeutics for ALS
  • Specific focus areas include:
    • Development of high-throughput screens and model systems
    • Development of pharmacological agents up to IND submission
    • Pilot cGMP production or formulation/ stability studies
  • Preliminary data are required, relevant to the phase of preclinical development
  • Transition plan for development beyond this award is required
  • Clinical trials are not allowed under this mechanism.
  • The maximum period of performance is 3 years.
  • The maximum allowable funding for the entire period of performance is $1,500,000 in direct costs.
  • More cost-effective studies not requesting the full funding amount are encouraged.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.
Therapeutic Idea Award Investigators at all academic levels
  • Supports early stage research relative to novel therapeutic development for ALS
  • Studies should be hypothesis-based but have a clearly defined impact on and relevance to therapeutic development for ALS
  • Innovation and impact are primary criteria
  • Preliminary data are not required
  • The maximum period of performance is 2 years.
  • The maximum allowable funding for the entire period of performance is $400,000 in direct costs.
  • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.

All applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the Grants.gov website upon official announcement of funding opportunity release. Submission deadlines will not be available until the program announcements are released. Requests for email notification of the program announcements release may be sent to help@cdmrp.org.

A pre-application is required and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to the pre-application deadline. Applications must be submitted through the federal government single-entry portal, Grants.gov.

Requests for email notification of the release of CDMRP program announcements may be sent to help@cdmrp.org. For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact: